PHVS

Pharvaris N.V. NASDAQ

Healthcare ·Biotechnology ·NL · pharvaris.com

$30.02

Mkt Cap $2.0B

52w Low $14.59 93.2% of range 52w High $31.14

50d MA $27.64 200d MA $24.99

P/E (TTM) -9.9x

EV/EBITDA -6.5x

P/B 6.4x

Debt/Equity 0.0x

ROE —

P/FCF -10.2x

RSI (14) —

ATR (14) —

Beta -2.58

50d MA $27.64

200d MA $24.99

Avg Volume 161.7K

About

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering fro…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Apr 2, 2026	AMC	-0.71	-0.85	-18.3%	28.56	+0.7%	-0.7%	-2.5%	-3.5%	-5.2%	-6.8%	+5.1%	—
Nov 12, 2025	AMC	-0.78	-0.70	+10.3%	25.81	+0.3%	-6.0%	-8.8%	-3.4%	-7.1%	-4.9%	-6.4%	—
Aug 12, 2025	AMC	-0.87	-0.94	-8.0%	21.09	+2.3%	+1.6%	+9.0%	+5.7%	+5.1%	+10.3%	+11.4%	—
May 13, 2025	AMC	-0.80	-0.89	-11.2%	16.11	+1.7%	-0.2%	-1.2%	+2.8%	+3.6%	+7.1%	+7.0%	—
Mar 31, 2025	AMC	—	-0.93	—	15.70	-1.3%	-5.5%	-4.8%	-6.9%	-9.0%	-15.9%	+17.7%	—
Nov 13, 2024	AMC	-0.66	-0.85	-28.8%	20.04	-0.1%	+2.5%	+1.5%	+4.4%	+2.3%	+2.3%	-8.2%	—
Aug 14, 2024	AMC	-0.57	-0.59	-3.5%	16.90	+0.2%	+13.6%	+10.9%	+10.7%	+5.5%	+5.3%	+23.8%	—
May 8, 2024	AMC	-0.56	-0.56	+0.0%	20.85	-0.6%	-1.3%	+2.9%	+1.5%	-0.2%	+6.0%	-24.8%	—
Apr 3, 2024	AMC	-0.58	-0.82	-41.4%	22.29	-3.1%	+0.6%	+1.2%	+2.0%	+3.8%	-0.1%	+1.4%	—
Nov 2, 2023	AMC	-0.67	-0.63	+6.0%	17.18	+1.7%	+7.6%	-1.2%	+1.1%	+0.1%	-2.5%	+6.1%	—
Aug 7, 2023	AMC	-0.71	-0.69	+2.8%	17.52	+1.5%	+3.2%	-1.5%	+4.5%	+5.9%	+5.1%	+19.9%	—
May 8, 2023	AMC	-0.81	-0.72	+11.1%	9.26	-0.6%	-8.2%	-8.2%	-11.3%	-13.6%	-12.5%	-11.0%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 7	Wedbush	Maintains	Outperform → Outperform	—	$28.37	$28.50	+0.5%	-1.9%	-2.9%	-4.6%	-6.1%	-1.7%
Apr 6	RBC Capital	Maintains	Outperform → Outperform	—	$28.56	$28.75	+0.7%	-0.7%	-2.5%	-3.5%	-5.2%	-6.8%
Mar 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$28.00	$27.49	-1.8%	-4.4%	-4.3%	-7.7%	-7.5%	-5.3%
Dec 4	BofA Securities	Maintains	Neutral → Neutral	—	$29.37	$29.18	-0.6%	-5.7%	-10.0%	-13.7%	-18.1%	-19.4%
Dec 4	Oppenheimer	Maintains	Outperform → Outperform	—	$29.37	$29.18	-0.6%	-5.7%	-10.0%	-13.7%	-18.1%	-19.4%
Dec 4	Guggenheim	Maintains	Buy → Buy	—	$29.37	$29.18	-0.6%	-5.7%	-10.0%	-13.7%	-18.1%	-19.4%
Dec 4	Morgan Stanley	Maintains	Overweight → Overweight	—	$29.37	$29.18	-0.6%	-5.7%	-10.0%	-13.7%	-18.1%	-19.4%
Dec 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$24.12	$24.13	+0.0%	+21.8%	+14.8%	+9.5%	+5.1%	-0.3%
Nov 14	Morgan Stanley	Maintains	Overweight → Overweight	—	$24.26	$24.36	+0.4%	-2.9%	+2.7%	-1.2%	+1.2%	-0.2%
Nov 13	Wedbush	Maintains	Outperform → Outperform	—	$25.81	$25.88	+0.3%	-6.0%	-8.8%	-3.4%	-7.1%	-4.9%
Nov 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$25.81	$25.88	+0.3%	-6.0%	-8.8%	-3.4%	-7.1%	-4.9%
Oct 9	BofA Securities	Upgrade	Underperform → Neutral	—	$22.98	$23.62	+2.8%	-0.6%	-4.4%	-4.0%	-8.8%	-5.2%
Aug 13	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$21.09	$21.58	+2.3%	+1.6%	+9.0%	+5.7%	+5.1%	+10.3%
Jun 5	Wedbush	Maintains	Outperform → Outperform	—	$16.62	$16.61	-0.1%	-3.4%	+1.0%	+8.5%	+9.0%	+2.6%
May 14	Wedbush	Maintains	Outperform → Outperform	—	$16.11	$16.38	+1.7%	-0.2%	-1.2%	+2.8%	+3.6%	+7.1%
May 14	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$16.11	$16.38	+1.7%	-0.2%	-1.2%	+2.8%	+3.6%	+7.1%
Mar 3	Citizens Capital Markets	Maintains	Market Outperform → Market Outperform	—	$15.90	$16.05	+0.9%	-3.6%	-2.8%	-5.7%	-2.8%	-5.6%
Jan 31	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$17.73	$18.28	+3.1%	-0.7%	-3.3%	-3.2%	-1.1%	+3.0%
Sep 6	Oppenheimer	Maintains	Outperform → Outperform	—	$19.10	$19.57	+2.5%	+0.1%	+3.9%	+12.0%	+9.8%	+7.4%
Jul 3	Oppenheimer	Maintains	Outperform → Outperform	—	$16.85	$17.19	+2.0%	+0.9%	-1.2%	+3.4%	+3.0%	+5.2%
May 9	Wedbush	Maintains	Outperform → Outperform	—	$20.85	$20.72	-0.6%	-1.3%	+2.9%	+1.5%	-0.2%	+6.0%
Apr 22	Morgan Stanley	Maintains	Overweight → Overweight	—	$19.16	$19.50	+1.8%	+8.9%	+11.1%	+10.9%	+18.8%	+21.9%
Apr 15	Morgan Stanley	Maintains	Overweight → Overweight	—	$21.90	$21.75	-0.7%	-8.0%	-4.1%	-3.2%	-15.9%	-12.5%
Apr 11	Wedbush	Maintains	Outperform → Outperform	—	$22.27	$23.94	+7.5%	+0.2%	-1.7%	-9.5%	-5.7%	-4.8%
Apr 11	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$22.27	$23.94	+7.5%	+0.2%	-1.7%	-9.5%	-5.7%	-4.8%
Mar 19	Wedbush	Maintains	Outperform → Outperform	—	$24.83	$24.85	+0.1%	+4.7%	+0.4%	+0.7%	-1.9%	-14.4%
Mar 2	Oppenheimer	Maintains	Outperform → Outperform	—	$39.23	$38.48	-1.9%	-1.2%	-1.9%	-14.3%	-26.7%	-31.0%
Mar 2	BofA Securities	Maintains	Neutral → Neutral	—	$39.23	$38.48	-1.9%	-1.2%	-1.9%	-14.3%	-26.7%	-31.0%
Mar 2	SVB Leerink	Maintains	Outperform → Outperform	—	$39.23	$38.48	-1.9%	-1.2%	-1.9%	-14.3%	-26.7%	-31.0%
Mar 2	Morgan Stanley	Maintains	Overweight → Overweight	—	$39.23	$38.48	-1.9%	-1.2%	-1.9%	-14.3%	-26.7%	-31.0%

Data updated apr 26, 2026 7:38pm · Source: massive.com